GW Pharmaceuticals (NASDAQ:GWPH) Has Just Had Its Target Price Cut by Analysts at Leerink Swann to $129.00


Analysis: GW Pharmaceuticals (NASDAQ:GWPH) Stock Target Increased Today

In a recent research report finalized by Leerink Swann on 8 December, the firm, GW Pharmaceuticals (NASDAQ:GWPH), had their target downgraded to $129.00. Analusts presently have a solid Outperform rating on the stock.

From a total of 6 analysts covering GW Pharmaceuticals (NASDAQ:GWPH) stock, 5 rate it a ”Buy”, 0 a “Sell”, and 0 a ”Hold”. This means that 100% of the ratings are positive. The highest target price is $150 while the lowest target price is $130. The mean of all analyst targets is $138.83 with a 57.88% above today’s ($85.35) stock price. GW Pharmaceuticals was the topic of 4 analyst reports since August 13, 2015 according to the firm StockzIntelligence Inc. Roth Capital initiated shares on November 30 with “Buy” rating. Morgan Stanley initiated GWPH stock in a recent report from August 13 with “Overweight” rating.

The stock increased 3.78% or $3.11 during the last trading session, striking $85.35. Approximately shares of stock traded hands. GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH) has declined 21.55% since May 6, 2015 and is downtrending. It has underperformed by 20.75% the S&P500.

GW Pharmaceuticals (NASDAQ:GWPH) Has Just Had Its Target Price Cut by Analysts at Leerink Swann to $129.00

GW Pharmaceuticals plc is a United Kingdom biopharmaceutical company. The company has a market cap of $1.82 billion. The Firm is engaged developing a portfolio of cannabinoid medicines, including Sativex for the treatment of multiple sclerosis spasticity and cancer pain, and Epidiolex for the treatment of childhood epilepsy. It currently has negative earnings. The Firm also engaged in developing cannabinoids, medicines containing controlled substances, as well as plant prescription pharmaceutical products.

According to Zacks Investment Research, “GW Pharmaceuticals plc is a biopharmaceutical company focused on discovering, developing and commercializing therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. The Company’s lead product, Sativex is used for the treatment of MS symptoms, cancer pain, and neuropathic pain. It operates primarily in the United Kingdom, Europe, the United States, Canada, and Asia. GW Pharmaceuticals plc is based in Salisbury, the United Kingdom.” Get a free copy of the Zacks research report on GW Pharmaceuticals PLC- ADR (GWPH).